BTIG Remains Positive on NeoGenomics (NEO) Following Q4 Results, Guidance; Affirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
NeoGenomics Reports Record Revenue of $27.2 Million and Record Adjusted EBITDA of $2.9 Million in Fourth Quarter, Driven by Strong Volume Gains
March 1, 2016 7:01 AM ESTFT. MYERS, Fla., March 1, 2016 /PRNewswire/ --Â NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2015.
Fourth Quarter 2015 Highlights:
25% growth in base(1) test volume 12% reduction in Avg. Cost-per-test in base(1) business Record Adjusted EBITDA(2) of $2.9 million (even with $2.1 million of FISH reductions) Adjusted Diluted EPS(2) of $0.05 per share and Diluted EPS of ($0.03) per shareFull Year 2015 Highlights:
25% growth... More